See more : Cronos Australia Limited (CAU.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Syncom Formulations (India) Limited (SYNCOMF.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Syncom Formulations (India) Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- PT Bank BTPN Tbk (BTPN.JK) Income Statement Analysis – Financial Results
- Tricon Residential Inc. (TCN.TO) Income Statement Analysis – Financial Results
- Youngwire Co., Ltd. (012160.KS) Income Statement Analysis – Financial Results
- ZeroFox Holdings, Inc. (ZFOX) Income Statement Analysis – Financial Results
- Jai Corp Limited (JAICORPLTD.BO) Income Statement Analysis – Financial Results
Syncom Formulations (India) Limited (SYNCOMF.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.syncomformulations.com
About Syncom Formulations (India) Limited
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations. It also offers anemia tablet and syrup, lycopene, minerals and vitamins capsules, products for eradication of vaginal pathogens, capsules for the treatment of menopause, herbal uterine tonic, syrup for the treatment lactation insufficiency, cough suppressants, liver tonic, medicine for burning urination, and nutritional supplements. In addition, the company engages in the trading of commodities and renting of properties. Further, it exports its products. The company offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.59B | 2.22B | 2.18B | 2.39B | 2.00B | 1.82B | 1.54B | 1.79B | 1.84B | 1.73B | 1.51B | 1.15B | 1.18B | 763.24M | 854.06M | 575.64M | 678.44M | 576.33M |
| Cost of Revenue | 1.65B | 1.50B | 1.47B | 1.67B | 1.57B | 1.41B | 1.14B | 1.32B | 1.36B | 1.20B | 1.02B | 799.64M | 1.00B | 163.52M | 761.91M | 508.40M | 610.96M | 527.92M |
| Gross Profit | 942.40M | 726.38M | 709.74M | 722.43M | 428.27M | 408.79M | 403.78M | 470.50M | 478.22M | 532.68M | 495.71M | 349.85M | 181.32M | 599.72M | 92.15M | 67.24M | 67.47M | 48.41M |
| Gross Profit Ratio | 36.35% | 32.65% | 32.58% | 30.19% | 21.40% | 22.46% | 26.22% | 26.22% | 26.00% | 30.72% | 32.77% | 30.44% | 15.31% | 78.58% | 10.79% | 11.68% | 9.95% | 8.40% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 22.01M | 26.24M | 18.86M | 14.17M | 13.04M | 13.31M | 14.07M | 75.14M | 4.60M | 3.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 272.56M | 233.16M | 263.99M | 169.01M | 118.68M | 147.07M | 144.49M | 120.94M | 89.02M | 136.97M | 118.28M | 74.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.78M |
| SG&A | 294.56M | 259.40M | 282.85M | 183.18M | 131.72M | 160.38M | 158.56M | 196.08M | 93.62M | 140.71M | 118.28M | 74.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.78M |
| Other Expenses | 647.84M | 45.21M | 36.61M | 37.85M | 43.95M | 43.33M | 35.82M | 22.10M | 9.44M | 5.02M | 4.46M | 4.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 942.40M | 561.85M | 536.99M | 372.37M | 300.94M | 330.39M | 324.04M | 337.67M | 337.52M | 384.60M | 364.06M | 272.55M | 122.54M | 594.88M | 18.28M | 6.47M | 7.29M | -21.42M |
| Cost & Expenses | 2.59B | 2.06B | 2.01B | 2.04B | 1.87B | 1.74B | 1.46B | 1.66B | 1.70B | 1.59B | 1.38B | 1.07B | 1.13B | 758.39M | 780.18M | 514.87M | 618.25M | 506.50M |
| Interest Income | 51.45M | 47.24M | 39.32M | 13.50M | 8.26M | 7.34M | 7.51M | 8.70M | 12.61M | 14.75M | 6.73M | 7.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 43.56M | 31.89M | 18.28M | 1.93M | 5.47M | 2.19M | 2.66M | 3.07M | 708.56K | 2.13M | 3.55M | 4.29M | 4.17M | 3.99M | 5.47M | 5.32M | 1.83M | 584.30K |
| Depreciation & Amortization | 47.22M | 45.39M | 39.48M | 40.35M | 40.61M | 40.03M | 37.30M | 31.23M | 29.98M | 34.32M | 30.73M | 29.10M | 27.16M | 24.47M | 21.74M | 14.01M | 17.81M | 14.70M |
| EBITDA | 430.31M | 341.47M | 319.59M | 450.31M | 218.77M | 169.24M | 159.60M | 194.53M | 192.35M | 192.80M | 173.55M | 106.40M | 85.94M | 32.94M | 95.62M | 74.78M | 78.00M | 84.53M |
| EBITDA Ratio | 16.60% | 15.34% | 14.65% | 18.72% | 10.97% | 9.29% | 10.39% | 10.83% | 10.48% | 11.61% | 11.47% | 9.26% | 7.25% | 4.32% | 11.20% | 12.99% | 11.50% | 14.67% |
| Operating Income | 251.72M | 138.85M | 147.48M | 287.20M | 75.17M | 33.48M | 36.67M | 136.85M | 151.57M | 151.33M | 134.81M | 80.13M | 58.78M | 8.48M | 73.88M | 60.77M | 60.19M | 69.83M |
| Operating Income Ratio | 9.71% | 6.24% | 6.77% | 12.00% | 3.76% | 1.84% | 2.38% | 7.63% | 8.24% | 8.73% | 8.91% | 6.97% | 4.96% | 1.11% | 8.65% | 10.56% | 8.87% | 12.12% |
| Total Other Income/Expenses | 87.81M | 126.88M | 114.28M | 119.84M | 45.57M | 48.35M | 40.41M | 23.10M | 9.44M | 5.02M | 4.46M | 4.37M | -4.17M | -362.69K | -5.47M | -5.32M | -1.83M | -584.30K |
| Income Before Tax | 339.53M | 265.73M | 261.76M | 407.04M | 172.89M | 126.75M | 120.15M | 159.95M | 161.01M | 156.35M | 139.26M | 84.49M | 54.61M | 4.48M | 68.41M | 55.45M | 58.36M | 69.25M |
| Income Before Tax Ratio | 13.10% | 11.94% | 12.02% | 17.01% | 8.64% | 6.97% | 7.80% | 8.91% | 8.76% | 9.02% | 9.21% | 7.35% | 4.61% | 0.59% | 8.01% | 9.63% | 8.60% | 12.02% |
| Income Tax Expense | 86.39M | 65.02M | 63.86M | 115.32M | 30.36M | 15.85M | 33.68M | 53.43M | 57.45M | 58.78M | 46.10M | 27.93M | 19.55M | 2.44M | 24.27M | 29.01M | 22.50M | 28.47M |
| Net Income | 253.14M | 200.71M | 197.90M | 291.72M | 142.53M | 110.90M | 86.47M | 106.52M | 103.56M | 97.57M | 93.17M | 56.56M | 35.06M | 2.04M | 44.13M | 26.44M | 35.86M | 40.77M |
| Net Income Ratio | 9.76% | 9.02% | 9.09% | 12.19% | 7.12% | 6.09% | 5.61% | 5.94% | 5.63% | 5.63% | 6.16% | 4.92% | 2.96% | 0.27% | 5.17% | 4.59% | 5.29% | 7.07% |
| EPS | 0.34 | 0.22 | 0.24 | 0.37 | 0.18 | 0.14 | 0.12 | 0.13 | 0.13 | 0.13 | 0.12 | 0.07 | 0.04 | 0.00 | 0.15 | 0.12 | 0.17 | 0.20 |
| EPS Diluted | 0.34 | 0.22 | 0.23 | 0.37 | 0.18 | 0.14 | 0.12 | 0.13 | 0.13 | 0.13 | 0.12 | 0.07 | 0.04 | 0.00 | 0.15 | 0.12 | 0.16 | 0.20 |
| Weighted Avg Shares Out | 744.54M | 928.53M | 816.85M | 789.95M | 780.65M | 780.65M | 720.60M | 780.65M | 780.65M | 780.65M | 559.14M | 780.65M | 780.65M | 780.65M | 298.44M | 217.88M | 207.11M | 201.62M |
| Weighted Avg Shares Out (Dil) | 744.54M | 928.53M | 873.16M | 789.95M | 780.65M | 792.15M | 720.60M | 819.38M | 780.65M | 780.65M | 559.14M | 780.65M | 780.65M | 780.65M | 298.44M | 229.25M | 207.11M | 201.62M |
Source: https://incomestatements.info
Category: Stock Reports